Saved in:
| Main Author: | |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Sociedad Venezolana de Farmacología Clínica y Terapéutica
2005
|
| Subjects: | |
| Online Access: | https://www.redalyc.org/articulo.oa?id=55924206 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Metformin plus low glimepiride doses improve significantly homair and homabcell without hyperinsulinemia in patients with type 2 diabetes V. J. Bermúdez F. A. Bermúdez M. T. Medina M. A. Lemus H. A. Seyfi A. C. Ciszek R. A. Cano C. A. Briceño S A. J. Souki C. Cano E. M. Leal M. C. Cabrera M. J. Ambard Medicina HOMA Metformin Glimepiride Type 2 diabetes Insulinresistance Type 2 Diabetes mellitus is characterized by insulin resistance and defects in insulin secretion. These variables have been studied bythe euglycemic/hyperinsulinemic clamp and MinMod, which difficult the insulin resistance and b cell failure study in clinical practice. Theaim of this study was to evaluate three different anti-diabetic therapeutic options using a mathematical model (Homeostasis modelassessment, HOMA). Seventy type 2 diabetic patients were randomly assigned one of the next therapeutic options: A) Metformin + ADADiet + Physical activity (Walk, 60 minutes/day). B) Metformin + Glimepiride + ADA Diet + Physical activity. C) Only ADA diet + Physicalactivity. A blood sample was taken before and after the treatment to determine basal and post-prandial blood glucose, basal insulin andHbA1c and to calculate HOMAbcell and HOMAIR. Before treatment basal and post-prandial levels of glucose, HbA1c, basal insulin andHOMAIR and HOMAbcell were significantly different when compared to after treatment levels for each group (p<0.01). Significantdifferences were also found when comparing basal blood glucose reduction (51.8%; p<0.01), post-prandial blood glucose (55.0%;p<0.05), and HOMAIR (65.3%; p<0.01) of group B (Metformin + low glimepiride dose) with the other therapeutic options. We concludethat metformin plus glimepiride at a low dose is a more effective treatment for type 2 diabetes than other therapeutic options. HOMAIRand HOMAbcell are inexpensive and reliable methods to study IR and b cell function in DM2. 2005 artículo científico 0798-0264 https://www.redalyc.org/articulo.oa?id=55924206 en http://www.redalyc.org/revista.oa?id=559 Archivos Venezolanos de Farmacología y Terapéutica application/pdf Sociedad Venezolana de Farmacología Clínica y Terapéutica Archivos Venezolanos de Farmacología y Terapéutica (República Bolivariana de Venezuela) Num.2 Vol.24